Showing results (61-70 of 123) with videos related to

Sort By:
Pageof 13
The Lancet Regional Health. Europe|April 18, 2025
Correction to "Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trial" [The Lancet Regional Health-Europe 45, October 2024, 101020]Jade Ghosn, Lambert Assoumou, Moussa Ouattara, et al.
The Lancet. HIV|October 2, 2015
Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trialChad J Achenbach, Lambert Assoumou, Steven G Deeks, et al.
The Journal of Antimicrobial Chemotherapy|October 7, 2022
Impact on renal function of daily and on-demand HIV pre-exposure prophylaxis in the ANRS-PREVENIR studyGeoffroy Liegeon, Lambert Assoumou, Jade Ghosn, et al.
International Journal of Sexual Health : Official Journal of the World Association for Sexual Health|August 22, 2025
Trajectories of Chemsex Engagement Across Time Among PrEP-Using Men Who Have Sex with Men: Results from the French ANRS-Prévenir CohortEmils Sietins, Luis Sagaon-Teyssier, Adbourahmane Sow, et al.
The Journal of Antimicrobial Chemotherapy|October 25, 2020
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimenRomain Palich, Clotilde Allavena, Gilles Peytavin, et al.
AIDS (London, England)|January 26, 2026
Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/mL and history of K103N mutationGraeme Moyle, Lambert Assoumou, Nathalie De Castro, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 8, 2022
Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France areaChristine Katlama, Yasmine Dudoit, Julien Huyard, et al.
The Lancet. Infectious Diseases|December 4, 2025
Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trialGeorg M N Behrens, Lambert Assoumou, Geoffroy Liegeon, et al.
The Journal of Antimicrobial Chemotherapy|April 12, 2022
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 studyMaria Saumoy, Jose Luís Sánchez-Quesada, Lambert Assoumou, et al.
Annals of Internal Medicine|February 11, 2020
Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized TrialYves Lévy, Jean-Daniel Lelièvre, Lambert Assoumou, et al.
Pageof 13